The Importance of Glutamine Concentration in Plasma for Cancer Related Fatigue

The Importance of Glutamine Concentration in Plasma for Cancer Related Fatigue - Fatigue Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00003065

Enrollment

100

Registered

2011-04-29

Start date

2009-09-04

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G93.3

Interventions

Group 1: Questionnaires: NRS Nutritional Risc Score SGA Subjective Global Assessment Score HADS Hospital Anxiety and Depressen Scale CFS Cancer Fatigue Scale Survey of Karnofsky Index Survey of PINI-

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with solid tumor (e.g. colorectal carcinoma, stomach cancer, breast cancer, bronchial carcinoma, tumor in ENT region) and with causally determinded systemic therapy (radio- and/or chemo therapy). Concentration of hemoglobin 9 g/dl or above Patients without receiving blood transfusion or erythrocyte concentrate within last 4 weeks

Exclusion criteria

Exclusion criteria: Patients - under 18 years - not capable of understanding German language - with psychological disorder - with parenteral nutrition - with active infection, requiring treatment - with hematologic tumor (leukaemia) - with glutamine treatment during the last 4 weeks - with previous erythropoietin treatment - Pregnant or breast feeding women

Design outcomes

Primary

Measure	Time frame
The primary purpose of this trial is to evaluate whether Cancer Related Fatigue correlates with decreased Glutamine concentration. In- and out-patients who are treated with chemo- or radiotherapy at the Klinikum Großhadern will be included. There is only 1 visit destined. In order to evaluate the severity of the fatigue the patient has to fill out the Cancer Fatigue Scale. The Scale consists of 15 items, classified in physical, affective and cognitive symptoms. Fatigue is given in patiens with a value >=23.	—

Measure

Time frame

The primary purpose of this trial is to evaluate whether Cancer Related Fatigue correlates with decreased Glutamine concentration. In- and out-patients who are treated with chemo- or radiotherapy at the Klinikum Großhadern will be included. There is only 1 visit destined. In order to evaluate the severity of the fatigue the patient has to fill out the Cancer Fatigue Scale. The Scale consists of 15 items, classified in physical, affective and cognitive symptoms. Fatigue is given in patiens with a value >=23.

—

Secondary

Measure	Time frame
On visit date a blood sample will be taken from which Glutamine concentration will be determined. A value lower than 579 ± 9.2 µmol/l is defined as decreased. The Glutmamine value will be correlated with the Fatigue Score.	—

Countries

Germany

Contacts

Public ContactMarcus Schlemmer

Klinikum der Universität München, Campus Großhadern

Marcus.Schlemmer@med.uni-muenchen.de+49 (0)89 7095 – 4930

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026